X4 Pharmaceuticals Inc
NASDAQ:XFOR
X4 Pharmaceuticals Inc
NASDAQ:XFOR
Price:
3.29
USD
-4.36%
Market Cap:
$287.7m
Relative Value
The Relative Value of one
XFOR
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 3.29 USD,
X4 Pharmaceuticals Inc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
XFOR Relative Value
HIDDEN
Multiples Across Competitors
XFOR Competitors Multiples
X4 Pharmaceuticals Inc Competitors
X4 Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
X4 Pharmaceuticals Inc
NASDAQ:XFOR
|
291.2m USD | 8.2 | -2.9 | -2.5 | -2.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.4B USD | 6.7 | 169.4 | 16.4 | 23.3 | |
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD | 462 374.5 | -2 631.9 | -2 389.6 | -2 389.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.6B USD | 5.5 | 26.4 | 15.1 | 15.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
178.7B USD | 6 | 20.9 | 14.2 | 14.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.2B USD | 10.1 | 30.8 | 23.6 | 24.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.9B USD | 5.6 | 18 | 13.4 | 15.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.7B AUD | 3.2 | 16.6 | 11.4 | 14.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.3B EUR | 13.2 | 31.1 | 52.8 | 54.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
